Gene Therapy Cell Viability Assay: Methods, Standards, and Quality Control

Cell viability assay is a critical quality control test for gene therapy products, confirming that genetically modified cells and vector producer cultures maintain membrane integrity and metabolic function throughout manufacturing and at final release. This article provides a comprehensive technical overview of cell viability determination for gene therapy, covering testing samples, analytical methods, applicable standards such as USP 1046 and ISO 20391, and common applications in cell and gene therapy development.

Technical Overview

Cell viability assay is a core analytical test in the development and manufacture of gene therapy products, encompassing ex vivo genetically modified cells (such as CAR-T and TCR-T cells), viral vectors produced in mammalian or insect cell lines, and genetically engineered stem cell therapies. Because the therapeutic activity of most cell-based gene therapy products depends directly on the presence of functional living cells, viability is designated as a critical quality attribute (CQA) that must be quantified at multiple stages of the manufacturing process and at final product release.

Cell viability is not a single measurable property but an operational concept defined by the analytical method used. Membrane integrity assays, such as dye exclusion tests, report whether the plasma membrane remains intact; metabolic assays report enzymatic competence; and ATP-based assays report cellular energy status. A robust control strategy therefore requires a clear understanding of what each method measures and how the result correlates with product safety and potency.

Testing is typically performed under GMP conditions in accredited third-party laboratories or in-house QC laboratories following recognized standards and guidances, including USP General Chapter 1046 (Cell and Gene Therapy Products), USP General Chapter 1047 (Gene Therapy Products), European Pharmacopoeia general chapter 2.7.29 (Nucleated Cell Count and Viability), ISO 20391-1 (biotechnology, cell counting, general requirements), and ISO 20391-2 (experimental design and statistical analysis to quantify counting method performance).

Testing Samples

Genetically Modified Immune Cell Products

Autologous and allogeneic T cells, NK cells, and other immune cells engineered with viral vectors, such as lentiviral or retroviral vectors encoding chimeric antigen receptors. Viability is assessed after activation, transduction, expansion, formulation, and post-thaw, because each unit operation imposes stress that can reduce cell fitness.

Viral Vector Producer Cells and Harvest Material

Producer cell lines such as HEK293, Vero, and Sf9 used for AAV, adenoviral, lentiviral, or retroviral vector manufacturing. Cell viability monitoring at transfection, infection, and harvest confirms culture health and supports interpretation of vector yield and impurity profiles.

Genetically Modified Stem Cell Products

Mesenchymal stromal cells, hematopoietic stem cells, and iPSC-derived cells subjected to genetic modification. Viability measurement for these products often requires methods compatible with clumps, aggregates, and matrix-embedded cells.

In-Process and Stability Samples

Intermediate process samples, cryopreserved aliquots, and shipped product. Viability kinetics during storage and post-thaw recovery are critical for establishing shelf life, holding times, and transport conditions.

Testing Items

Depending on product type, development stage, and regulatory expectations, the following viability-related attributes are commonly evaluated:

• Total nucleated cell count (TNC) and viable cell count
• Viability percentage (viable cells relative to total cells)
• Membrane integrity status (live, dying, and dead populations)
• Apoptosis and necrosis discrimination (early apoptotic, late apoptotic, and necrotic fractions)
• Metabolic activity index (dehydrogenase or reductase function)
• Intracellular ATP content as an energy-status surrogate
• Post-thaw viability recovery and viability stability over time

Testing Methods

Dye Exclusion Counting and Automated Image Cytometry

Trypan blue and erythrosin B exclusion, performed by hemocytometer or automated image-based counters, remain the reference approach for routine viable cell counting. Fluorescent double staining with acridine orange and propidium iodide improves accuracy for samples containing debris, platelets, or red blood cells, because acridine orange stains all nucleated cells while propidium iodide enters only membrane-compromised cells. These methods should meet the counting method performance requirements described in ISO 20391-1 and ISO 20391-2.

Flow Cytometric Viability Analysis

Flow cytometry provides single-cell, multiparameter viability assessment. Non-permeant DNA dyes such as propidium iodide, 7-AAD, and DRAQ7 identify dead cells, while fixable amine-reactive viability dyes allow viability measurement in samples that require fixation or intracellular staining. Combined Annexin V and propidium iodide staining discriminates viable cells (Annexin V-negative and PI-negative), early apoptotic cells (Annexin V-positive and PI-negative), and late apoptotic or necrotic cells (double-positive), delivering mechanistic insight beyond a single viability number.

Metabolic Activity Assays

Tetrazolium reduction assays (MTT, XTT, MTS, WST-1) quantify the activity of cellular dehydrogenases that convert substrate into colored formazan products, and resazurin-based assays measure reductase activity through a fluorescent readout. These methods are well suited to potency-linked viability assessment, cytotoxicity screening of process reagents, and high-throughput process development, although results can be confounded by metabolic shifts unrelated to cell death.

ATP Bioluminescence Assays

Luciferase-based ATP quantification provides a rapid, sensitive, and homogeneous measure of intracellular ATP, which declines rapidly when cells lose membrane integrity. The assay offers a wide linear range and excellent reproducibility, making it suitable for viability assessment of vector producer cell cultures and for supporting cytotoxicity evaluations during process characterization.

Fluorescence Microscopy Live/Dead Staining

Calcein-AM is converted by intracellular esterases in viable cells into a green fluorescent product, while ethidium homodimer or propidium iodide labels the nuclei of membrane-compromised cells in red. Direct fluorescence microscopy or automated imaging quantifies both populations and provides visual documentation, which is particularly valuable for heterogeneous or aggregated stem cell products.

Method Validation and Data Integrity

Regardless of platform, methods intended for GMP release or in-process control should be validated or qualified for accuracy, precision, specificity, linearity, range, limit of detection, and robustness in line with ICH Q2 expectations and ISO 20391-2 for counting methods. Instrument calibration with certified counting reference materials, system suitability testing, and compliant electronic records ensure that viability data are reliable and auditable.

Applications

Cell viability measurement supports the entire gene therapy product lifecycle:

• Batch release testing of autologous and allogeneic genetically modified cell products against defined acceptance criteria, commonly a minimum of 70 percent viable cells as referenced in USP 1046 and multiple regulatory guidance documents
• In-process control during cell activation, transduction, expansion, washing, formulation, and cryopreservation steps
• Monitoring of producer cell culture health during viral vector manufacturing to support yield investigation and impurity control
• Stability studies, shelf-life determination, and post-thaw recovery characterization
• Shipping and distribution validation, including temperature excursion assessment
• Comparability and bridging studies after process, site, or scale changes
• Analytical support for IND submissions, clinical trials, and marketing authorization applications

FAQ

What viability threshold is generally required for product release?

For most infused cell therapy products, regulatory expectations and compendial guidance typically require viability of at least 70 percent at release, with product-specific justification. Some genetically modified cell products may require higher thresholds, and the rationale should be supported by clinical and analytical data.

Which viability method is most appropriate?

The choice depends on the sample matrix, throughput needs, and intended use of the data. Dye exclusion counting is suitable for routine release counts, flow cytometry is preferred when apoptosis discrimination or multiparameter characterization is needed, and metabolic or ATP assays are advantageous for high-throughput screening and potency-linked assessments.

How does viability differ from potency?

Viability measures the proportion of cells with intact membranes and basic metabolic function, whereas potency measures the biological activity required to achieve the intended therapeutic effect. Viability is a necessary but not sufficient indicator of potency, and both attributes are evaluated within an integrated control strategy.

Can viability be assessed after cryopreservation?

Yes. Post-thaw viability and recovery are critical quality parameters for cryopreserved gene therapy products. Testing is typically performed immediately after thaw and, where relevant, after a defined post-thaw holding period to reflect real clinical use conditions.

What sample conditions are required for accurate testing?

Samples should be representative, well mixed, processed promptly, and protected from extreme temperatures. Method-specific parameters such as dye contact time, dilution linearity, and replicate number must be predefined to control analytical variability.

Are viability methods subject to regulatory inspection?

Yes. Viability results included in GMP release or stability data must be generated with validated or qualified methods, calibrated instruments, trained analysts, and compliant documentation in accordance with GMP expectations and applicable pharmacopoeial and ISO standards.